Re­gen­eron hands off ex-US rights for cho­les­terol dis­or­der drug to rare dis­ease spe­cial­ist Ul­tragenyx

Re­gen­eron has held high hopes for evinacum­ab, a rare cho­les­terol dis­or­der drug that earned a first-in-class nod from the FDA ear­ly last year, as a cen­ter­piece of its car­diometa­bol­ic fran­chise. Now, the com­pa­ny is tap­ping an ul­tra-rare spe­cial­ist to take evinacum­ab to the next lev­el abroad.

Re­gen­eron will re­ceive $30 mil­lion in up­front cash and a po­ten­tial $63 mil­lion in down­stream mile­stones from Ul­tragenyx for ex-US li­cens­ing rights to Evkeeza (evinacum­ab), an ANGPTL3 block­er with an FDA ap­proval to treat a rare cho­les­terol dis­or­der along­side LDL-C low­er­ing ther­a­py and di­et, the com­pa­nies said Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.